Microarray: an instrument for cancer surgeons of the future?
- 1 July 2010
- journal article
- research article
- Published by Wiley in Anz Journal of Surgery
- Vol. 80 (7-8), 531-536
- https://doi.org/10.1111/j.1445-2197.2010.05379.x
Abstract
Microarray enables the study of thousands of genes simultaneously. While still in its infancy as a technique and with a number of barriers to be overcome, microarray is allowing scientists to thoroughly examine the molecular pathways of cancer pathogenesis. However, the adoption of microarray as a clinically applicable technique has been slow coming. Current literature suggests roles in the diagnosis of tumours of unknown origin, in the evaluation of prognostic markers, and in guiding treatment for recurrent and resistant malignancy. This review outlines the science of microarray and draws on clinical examples, including osteosarcoma, breast, prostate and pancreatic carcinomas, to highlight the potential of microarray as a technique of surgical importance.Keywords
This publication has 31 references indexed in Scilit:
- Towards Improved Cancer Diagnosis and Prognosis Using Analysis of Gene Expression Data and Computer Aided ImagingExperimental Biology and Medicine, 2009
- Molecular assignment of tissue of origin in cancer of unknown primary may not predict response to therapy or outcome: A systematic literature reviewCancer Treatment Reviews, 2009
- Gene expression profiling may improve diagnosis in patients with carcinoma of unknown primaryBritish Journal of Cancer, 2008
- An Expression-Based Site of Origin Diagnostic Method Designed for Clinical Application to Cancer of Unknown OriginCancer Research, 2005
- Molecular medicine: a clinician's primer on microarraysInternal Medicine Journal, 2004
- Multi-Platform, Multi-Site, Microarray-Based Human Tumor ClassificationThe American Journal of Pathology, 2004
- Accurate Molecular Classification of Human Cancers Based on Gene Expression Using a Simple Classifier with a Pathological Tree-Based FrameworkThe American Journal of Pathology, 2003
- Affymetrix, Inc.Pharmacogenomics, 2002
- Multiclass cancer diagnosis using tumor gene expression signaturesProceedings of the National Academy of Sciences, 2001
- Organ-Specific Molecular Classification of Primary Lung, Colon, and Ovarian Adenocarcinomas Using Gene Expression ProfilesThe American Journal of Pathology, 2001